Pegvaliase-pqpz
Brand names: Palynziq · Active ingredient: Pegvaliase
In short: PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
What is Pegvaliase-pqpz used for?
PALYNZIQ is indicated to reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.
âš Boxed warning (FDA's strongest warning)
Anaphylaxis has been reported after administration of PALYNZIQ and may occur at any time during treatment .
Administer the initial dose of PALYNZIQ under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient's and observer's (if applicable) ability to recognize signs and symptoms of anaphylaxis and administer epinephrine, if needed .
Consider having an adult observer for patients who may need assistance in recognizing and managing anaphylaxis during PALYNZIQ treatment. If an adult observer is needed, the observer should be present during and for at least 60 minutes after PALYNZIQ administration, should be able to administer epinephrine, and call for emergency medical support upon its use .
Prescribe epinephrine to all patients treated with PALYNZIQ. Prior to the first dose, instruct the patient and observer (if applicable) how to recognize the signs and symptoms of anaphylaxis, how to properly administer epinephrine, and to seek immediate medical care upon its use. Instruct patients to carry epinephrine with them at all times during treatment with PALYNZIQ .
Consider the risks and benefits of readministering PALYNZIQ following an episode of anaphylaxis. If the decision is made to readminister PALYNZIQ, readminister the first dose under the supervision of a healthcare provider equipped to manage anaphylaxis and closely observe the patient for at least 60 minutes following the dose . …
Pegvaliase-pqpz dosage
Treatment with PALYNZIQ should be managed by a healthcare provider experienced in the management of PKU.
Obtain baseline blood phenylalanine concentration before initiating treatment.
Consider premedication with an H1-receptor antagonist, H2-receptor antagonist, and/or antipyretic based upon individual patient tolerability .
Induction
The recommended initial induction dosage for PALYNZIQ is 2.5 mg subcutaneously once weekly for 4 weeks. Administer the initial dose under the supervision of a healthcare provider .
Titration
Titrate the PALYNZIQ dosage in a step-wise manner, based on tolerability, over at least 5 weeks, to achieve a dosage of 20 mg subcutaneously once daily according to Table 1.
Maintenance
Therapeutic response may not be achieved until the patient is titrated to an effective maintenance dosage of PALYNZIQ. Use the lowest effective and tolerated dosage of PALYNZIQ.
Assess patient tolerability, blood phenylalanine concentrations, and dietary protein and phenylalanine intake throughout treatment.
Individualize the maintenance dosage to achieve blood phenylalanine control (blood phenylalanine concentrations less than or equal to 600 micromol/L), taking into account patient tolerability to PALYNZIQ and dietary protein and phenylalanine intake .
Maintain the PALYNZIQ dosage at 20 mg once daily for at least 24 weeks. Consider increasing the PALYNZIQ dosage to 40 mg once daily in patients who have been on 20 mg once daily continuously for at least 24 weeks without achieving blood phenylalanine control. Consider increasing the PALYNZIQ dosage to a maximum of 60 mg once daily in patients who have been on 40 mg once daily continuously for at least 16 weeks without achieving blood phenylalanine control.
Discontinuation
Discontinue PALYNZIQ in patients who have not achieved an adequate response after 16 weeks of continuous treatment with the maximum dosage of 60 mg once daily .
Treatment | PALYNZIQ Dosage | DurationAdditional time may be required prior to each dosage escalation based on patient tolerability.
Induction | 2.5 mg once weekly | 4 weeks
Titration | 2.5 mg twice weekly | 1 week
10 mg once weekly | 1 week
10 mg twice weekly | 1 week
10 mg four times per week | 1 week
10 mg once daily | 1 week
MaintenanceIndividualize treatment to the lowest effective and tolerated dosage. Consider increasing to 40 mg once daily in patients who have not achieved a response with 20 mg once daily continuous treatment for at least 24 weeks. Consider increasing to a maximum of 60 mg once daily in patients who have not achieved a response with 40 mg once daily continuous treatment for at least 16 weeks . …
How to take Pegvaliase-pqpz — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Anaphylaxis and Other Hypersensitivity Reactions
Advise patients that PALYNZIQ may cause hypersensitivity reactions, including anaphylaxis that can occur at any time. Instruct patients to recognize the signs and symptoms of anaphylaxis .
Instruct patients to carry epinephrine with them at all times during PALYNZIQ treatment. Instruct the patient and observer (if applicable) on the appropriate use of epinephrine for anaphylaxis .
Instruct patients who experience anaphylaxis to seek immediate medical care, discontinue therapy, and resume treatment only at the instruction of a healthcare provider .
PALYNZIQ REMS Program
PALYNZIQ is available only through a restricted program called the PALYNZIQ REMS . Inform the patient of the following notable requirements:
Patients must be enrolled in the PALYNZIQ REMS.
Patients must be educated about the risk of anaphylaxis by a certified prescriber to ensure they understand the risks and benefits of treatment with PALYNZIQ.
Patients must fill a prescription for epinephrine and carry it with them at all times. …
Warnings & precautions
Do not take this medicine if: None.
In PALYNZIQ Studies 1, 2, and 3 with an induction/titration/maintenance dosage regimen, 10% (29/285) of PALYNZIQ-treated patients experienced a total of 42 anaphylaxis episodes . The exposure-adjusted rate of anaphylaxis was highest during the induction and titration phases (0.25 episodes/person-years; 5% of PALYNZIQ-treated patients with at least one episode) and decreased in the maintenance phase (0.05 episodes/person-years; 7% of PALYNZIQ-treated patients with at least one episode). Signs and symptoms of anaphylaxis reported in PALYNZIQ-treated patients included syncope, hypotension, hypoxia, dyspnea, wheezing, chest discomfort/chest tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue), throat tightness, skin flushing, rash, urticaria, pruritus, and gastrointestinal symptoms (vomiting, nausea, diarrhea). Anaphylaxis occurred within 1 hour after injection in 81% of PALYNZIQ-treated patients (34/42 episodes); however, delayed episodes also occurred up to 48 hours after PALYNZIQ administration. Anaphylaxis occurred within the first year of dosing in 69% of PALYNZIQ-treated patients (29/42 episodes), but cases also occurred after one year of dosing and up to 1,604 days (4.4 years) into treatment. Management of anaphylaxis in PALYNZIQ-treated patients included: administration of epinephrine (48%; 20/42 episodes), corticosteroids (55%; 23/42 episodes), antihistamines (57%; 24/42 episodes), and/or oxygen (5%; 2/42 episodes). In these trials, 72% (21/29) of patients who experienced anaphylaxis were rechallenged with PALYNZIQ and 29% (6/21) of patients who were rechallenged had recurrence of anaphylaxis. All anaphylaxis episodes resolved without sequelae.
In Study 4, conducted in patients who were 12 to less than 18 years of age , premedication was administered to all patients. …
Pegvaliase-pqpz side effects
The following serious adverse reactions are discussed below and in other sections of labeling:
Anaphylaxis
Other Hypersensitivity Reactions
Injection Site Infections
Hypophenylalaninemia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials With Induction/Titration/Maintenance Dosage Regimen in Patients With PKU (Study 1, Study 2, and Study 3)
The data described below reflect a total treatment exposure of 789 patient-years in 285 patients who received PALYNZIQ in an induction/titration/maintenance regimen in a pooled safety analysis of a phase 2 study (Study 1), and 2 phase 3 studies (Studies 2 and 3, respectively) . Twelve patients aged 16-17 years at enrollment received PALYNZIQ as part of the overall induction/titration/maintenance population and are included in this analysis. Of the 285 patients, 229 patients were exposed to PALYNZIQ for 24 weeks, 209 patients were exposed for 1 year, 181 patients were exposed for 2 years, and 160 patients were exposed for 3 years or longer. The patient population was evenly distributed between male and female patients, the mean age was 29 years (range: 16 to 56 years), and 98% of patients were White. …
Drug interactions
In a single dose study of PALYNZIQ in adult patients with PKU, two patients receiving concomitant injections of medroxyprogesterone acetate suspension (a formulation containing PEG 3350) experienced a hypersensitivity reaction. One of the two patients experienced a hypersensitivity reaction on day 15 after a single PALYNZIQ dosage of 0.67 mg within 15 minutes following medroxyprogesterone acetate injectable suspension, and subsequently experienced anaphylaxis on day 89 within 30 minutes after the next dose of medroxyprogesterone acetate injectable suspension. The other patient experienced a hypersensitivity reaction on day 40 after a single PALYNZIQ dosage of 0.08 mg within 10 minutes following medroxyprogesterone acetate injectable suspension. Both patients had high anti-PEG IgG antibody titers at or around the time of the hypersensitivity reactions.
In PALYNZIQ clinical trials, the majority of patients developed anti-PEG IgM and IgG antibodies after treatment with PALYNZIQ . The clinical effects of concomitant treatment with different PEGylated products is unknown. Monitor patients treated with PALYNZIQ and concomitantly with other PEGylated products for hypersensitivity reactions including anaphylaxis.
About this medicine
Pegvaliase-pqpz is a phenylalanine-metabolizing enzyme that is composed of recombinant phenylalanine ammonia lyase (rAvPAL) conjugated to N-hydroxysuccinimide (NHS)-methoxypolyethylene glycol (PEG). rAvPAL is manufactured in Escherichia coli bacteria transformed with a plasmid containing the phenylalanine ammonia lyase (PAL) gene derived from Anabaena variabilis. During the rAvPAL manufacturing process, fermentation is carried out in nutrient medium containing the antibiotic kanamycin. However, kanamycin is cleared in the manufacturing process and is not detectable in the final product. rAvPAL is a homotetrameric protein with a molecular weight of 62 kD per monomer. To produce pegvaliase-pqpz, an average of nine (9) 20 kD PEG molecules are covalently bound (or conjugated) to each monomer of rAvPAL. The total molecular weight of pegvaliase-pqpz (rAvPAL-PEG) is approximately 1000 kD. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6dba844a-db02-44f8-8593-ce497ed9406c. Read the full official label on DailyMed.